Ultrasound Combined With Microbubbles Loading BDNF Retrovirus to Open BloodBrain Barrier for Treatment of Alzheimer's Disease.
Authors: Wang F, Wei XX, Chang LS, Dong L, Wang YL, Li NN
<b>Background:</b> Brain-derived nerve growth factor (BDNF) is a promising effective target for the treatment of Alzheimer's disease (AD). BDNF, which has a high molecular weight, has difficulty in crossing the blood-brain barrier (BBB). The study aimed to prepare microbubbles loading brain-derived nerve growth factor (BDNF) retrovirus (MpLXSN-BDNF), to verify the characteristics of the microbubbles, and to study the therapeutic effect of the microbubbles combined with ultrasound on the opening of the blood-brain barrier in an AD rat model. <b>Methods:</b> 32 adult male SD rats were randomly divided into four groups: control group, ultrasound + pLXSN-EGFP microbubble group (U + MpLXSN-BDNF), ultrasound + pLXSN-BDNF microbubble group, and ultrasound + microbubble + pLXSN-BDNF virus group (U + MpLXSN-BDNF), with eight rats in each group. At the same time, the left hippocampus of rats was irradiated with low-frequency focused ultrasound guided by MRI to open the blood-brain barrier (BBB). The effects of BDNF overexpression on AD rats were evaluated behaviorally before and 1 month after the treatment. The number of acetylcholinesterase (ChAT)-positive cells and the content of acetylcholine (ACh) in brain tissues were determined by immunohistochemistry and high-performance liquid chromatography (HPLC), respectively. IF staining of synaptic spines and Western blot of synaptophysin presented herein detected synaptic density recovery. <b>Results:</b> Signal intensity enhancement at the BBB disruption sites could be observed on the MR images. The behavioral evaluation showed that the times of crossing the original platform in the U + MpLXSN-BDNF group increased significantly after treatment. Immunohistochemistry and HPLC revealed that the number of ChAT-positive neurons and the contents of ACh in the brain were significantly decreased in the treated groups compared with the controls. IF staining of synaptic spines and Western blot data of synaptophysin showed that the U + MpLXSN-BDNF group can recover the synaptic loss better by BDNF supplementation than the other treatment groups. <b>Conclusion:</b> Ultrasound combined with viral microbubbles carrying BDNF can increase the transfection efficiency of brain neurons, promote the high expression of exogenous gene BDNF, and play a therapeutic role in the AD model rats.
Introduction
Purpose
Drug delivery with BBB opening
Study Objective
To prepare BDNF-carrying retroviral microbubbles and evaluate whether ultrasound-mediated BBB opening enhances BDNF delivery and therapeutic effect in an Alzheimer’s disease rat model.
Animal model / Human subject
rat, SD, 8-10 weeks, male
Disease model
Alzheimer's disease
MRI or image guidance method
MRI-guided low-frequency focused ultrasound targeting the left hippocampus
Targeted brain region(s)
Hippocampus
Cargo name and characteristics
BDNF-carrying retroviral microbubbles
Route of administration
intravenous
Outcomes and Safety
Summary of Outcomes
FUS+BDNF retroviral microbubbles improved spatial memory (increased platform crossings), recovered synaptic spine density, and increased synaptophysin expression; however, ChAT-positive neurons and ACh content were significantly decreased in treated groups compared to control
Duration of biological effect
1 month
Safety-related matter
No obvious hemorrhage or tissue damage observed via H&E staining.
Brain Region
Ultrasound Parameters
Ultrasound instrument
Vantage 256, Verasonics
FUS Frequency
1.0 MHz
FUS Intensity
Not reported in the provided text
FUS Pressure
0.5 MPa
FUS Mode
pulsed
Pulse duration
0.1 ms
Duration of a single FUS session
30 s
Focal Characteristics
Not reported
Treatment frequency
single session
We are open to feedback. If you see a mistake or have a suggestion, please contact us.
← Back to Search